Home / Pharmacology / Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf

Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf

Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf

Workbook and Casebook derives from the 12th edition of Goodman & Gilman’s The Pharmacological Basis of Therapeutics. The organization of the parent text has been retained and many of the tables and figures are the same. The editors have attempted to provide the most important concepts from the 12th edition of G&G in a user- friendly format without the elimination of salient pharmacological in formation. It is our intention that the Workbook and Casebook will complement the parent text and the second edition o Goodman & Gilman’s Manual of Pharmacology and therapeutics and be useful to students and educators who might need a companion text in an advanced pharmacology course.

Each Workbook and Casebook chapter begins with a statement of how it compare the 12th edition so that the reader can refer to the parent text to obtain additional in formation if necessary.

Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf chapters

(except or chapters on general principles) are formatted as follows:
• Learning Objectives
• Drugs Included in the Chapter Mechanisms o Action (and, where appropriate, Mechanisms
of Resistance) Table
• Clinical Cases
• Key Concepts
• Summary Quiz
• Summary able of Drugs that includes Drug Class, Drug Name, Clinical Uses, and Common and Unique Clinically
Important toxicities

Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf
Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf download

Goodman & Gilman’s Manual of Pharmacology and Therapeutics workbook and casebook pdf content

SECTION I 1
General Principles
1 Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2 Pharmacokinetics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3 Clinical and Environmental oxicity. . . . . . . . . . . . . . . . 40
4 Special Populations (Children and Elderly) . . . . . . . . . . 67
SECTION II 79
Neuropharmacology
5 Neurotransmission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
6 Cholinergic Pharmacology. . . . . . . . . . . . . . . . . . . . . . . . 95
7 Adrenergic, Dopaminergic, and
Serotonergic Pharmacology . . . . . . . . . . . . . . . . . . . . . . 118
8 Psychopharmacology. . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
9 Hypnotics, Sedatives, and Ethanol. . . . . . . . . . . . . . . . . 176
10 Opioid Pharmacology . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
11 Anesthetic Agents and Therapeutic Gases . . . . . . . . . . 210
12 Pharmacotherapy o the Epilepsies . . . . . . . . . . . . . . . . 225
13 Drug Therapy of Neurodegenerative Diseases. . . . . . . 238
14 Drug Addiction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254
SECTION III 267
Modulation o Cardiovascular Function
15 Drug Therapy o Hypertension, Edema, and
Disorders o Sodium and Water Balance . . . . . . . . . . . 268
16 Drug Therapy o Myocardial Ischemia . . . . . . . . . . . . . 289
17 Pharmacotherapy of Heart Failure . . . . . . . . . . . . . . . . 301
18 Antiarrhythmic Drugs. . . . . . . . . . . . . . . . . . . . . . . . . . . 312
19 Drug Therapy o Thromboembolic Disorders . . . . . . . 323
20 Drug Therapy of Dyslipidemias . . . . . . . . . . . . . . . . . . . 334

SECTION IV 345
Infammation, Immunomodulation,and Hematopoiesis
21 Histamine, Bradykinin, and Their Antagonists . . . . . . 346
22 Prostaglandins, NSAIDs, and
Pharmacotherapy of Gout. . . . . . . . . . . . . . . . . . . . . . . . 356
23 Immunotherapeutic Agents . . . . . . . . . . . . . . . . . . . . . . 375
24 Pulmonary Pharmacology . . . . . . . . . . . . . . . . . . . . . . . 389
25 Hematopoietic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . 405
SECTION V 421
Hormones and Hormone Antagonists
26 Introduction to Endocrinology:
The Hypothalamic-Pituitary Axis . . . . . . . . . . . . . . . . . 422
27 Thyroid and Antithyroid Drugs . . . . . . . . . . . . . . . . . . . 431
28 Estrogens, Progestins, Androgens,
and Contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441
29 ACTH, Adrenal Steroids, and
Pharmacology o the Adrenal Cortex . . . . . . . . . . . . . . 459
30 Endocrine Pancreas and Pharmacotherapy
o Diabetes Mellitus and Hypoglycemia . . . . . . . . . . . . 470
31 Drug Therapy o Mineral Ion Homeostasis
and Bone turnover Disorders . . . . . . . . . . . . . . . . . . . . 480

SECTION VI 489
Drugs Affecting Gastrointestinal Function
32 Pharmacotherapy o Gastric Acidity, Peptic
Ulcers, and Gastroesophageal Reflux Disease . . . . . . . 490
33 Drugs Used or the treatment o Bowel Disorders . . . 497
SECTION VII 511
Chemotherapy o Microbial Diseases
34 General Principles o Antimicrobial T erapy . . . . . . . 512
35 Chemotherapy o Malaria. . . . . . . . . . . . . . . . . . . . . . . . 520
36 Chemotherapy o Protozoal Infections: Amebiasis,
Giardiasis, richomoniasis, rypanosomiasis,
Leishmaniasis, and Other Protozoal In ections. . . . . . . 530
37 Chemotherapy o Helminth In ections. . . . . . . . . . . . . 536
38 SulFonamides, Trimethoprim-Sulfamethoxazole,
Quinolones, and Agents or Urinary
Tract Infections. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542
39 Penicillins, Cephalosporins, and
Other β-Lactam Antibiotics . . . . . . . . . . . . . . . . . . . . . . 549
40 Aminoglycosides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559
41 Protein Synthesis Inhibitors and
Miscellaneous Antibacterial Agents . . . . . . . . . . . . . . . 568
42 Chemotherapy o uberculosis, Mycobacterium
Avium Complex Disease, and Leprosy . . . . . . . . . . . . . 578
43 Antifungal Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588
44 Antiviral Agents and treatment
o HIV Infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600

SECTION VIII 625
Chemotherapy o Neoplastic Diseases
45 Cancer Chemotherapy and Cytotoxic Agents . . . . . . . 626
46 Target Anticancer  therapies. . . . . . . . . . . . . . . . . . . . 661

SECTION IX 689
Special Systems Pharmacology
47 Ocular Pharmacology . . . . . . . . . . . . . . . . . . . . . . . . . . . 690
48 Dermatological Pharmacology. . . . . . . . . . . . . . . . . . . . 707
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728

 

 

About admin

Check Also

Goodman and Gilman The Pharmacological Basis of Therapeutics 13th Edition 2018

Goodman and Gilman The Pharmacological Basis of Therapeutics 13th Edition 2018

Goodman and Gilman The Pharmacological Basis of Therapeutics 13th Edition 2018 Medicinal Pharmacology has emerged …

Leave a Reply

Your email address will not be published. Required fields are marked *